BNTX News & Events

BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMY) announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer, NSCLC. Key highlights include: First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care; Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes; Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials

BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMS) announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer, NSCLC. Key highlights include: First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care; Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes; Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials

Latest data shows the largest indicative borrow rate increases among liquid option names include: Prospect Capital (PSEC) 7.81% +5.13, T-REX 2X Long BMNR Daily Target ETF (BMNU) 12.28% +2.60, Wendy's (WEN) 11.62% +2.34, Tradr 2X Short SNDK Daily ETF (SNDQ) 33.41% +1.77, KULR Technology Group (KULR) 8.05% +1.40, GRANITESHARES 2X LONG PLTR DAILY ETF (PTIR) 3.79% +0.76, -1X SHORT VIX FUTURES ETF (SVIX) 8.93% +0.71, Angion Biomedica Corp (ELTX) 11.66% +0.68, BioNTech SE (BNTX) 2.12% +0.51, and ProShares UltraShort Lehman 20 plus Year Treasury (TBT) 6.21% +0.42.